Approach to the patient with a positive ANA
Interpreting antinuclear antibody results · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A positive antinuclear antibody is common in the healthy population and non-specific, so interpretation depends on the clinical context, titre, pattern and associated specific antibodies. The task is to avoid both overdiagnosis of connective tissue disease in asymptomatic people and missed diagnoses in symptomatic ones.
Red flags
- Objective organ involvement (nephritis, serositis, cytopenias)
- High-titre ANA with anti-dsDNA or anti-Sm positivity
- Raynaud with abnormal nailfold capillaroscopy (evolving SSc)
- Systemic features: fever, weight loss, arthritis, rash
- Thrombosis or pregnancy loss (antiphospholipid screen)
Assessment
Differential diagnosis
- Systemic lupus erythematosus
- Sjogren syndrome
- Systemic sclerosis
- Inflammatory myopathy
- Drug-induced lupus
- Healthy individual / other (infection, thyroid disease, malignancy)
Investigations
- ANA titre and immunofluorescence pattern (homogeneous, speckled, nucleolar, centromere)
- Extractable nuclear antigen panel (anti-dsDNA, Ro, La, Sm, RNP, Scl-70, centromere, Jo-1)
- Complement C3/C4 and FBC
- Urinalysis and renal function (lupus nephritis screen)
- CRP/ESR
- Targeted tests per symptoms (CK, Schirmer, nailfold capillaroscopy)
Management
- Interpret the ANA only in clinical context - do not test without a reason
- Assess titre: low-titre positivity (e.g. 1:40-1:80) is common and often not significant
- Use the immunofluorescence pattern to guide further testing (centromere -> limited SSc; nucleolar -> SSc; speckled -> ENA panel)
- Order specific antibodies (anti-dsDNA, ENA) rather than repeating ANA
- Look for objective features: synovitis, rash, serositis, cytopenias, renal involvement, sicca, Raynaud
- Screen for organ involvement if a connective tissue disease is suspected
- Reassure and avoid over-investigation in asymptomatic low-titre positives
- Refer symptomatic patients with supportive serology/organ features to rheumatology
Drugs & doses
No treatment for an isolated positive ANA without disease
Hydroxychloroquine — 200-400 mg PO OD (max 5 mg/kg/day) only once a defined connective tissue disease is diagnosed
Treatment otherwise directed by the specific diagnosis made
Disposition
Outpatient: reassure asymptomatic low-titre positives; refer symptomatic patients with supportive serology to rheumatology.
Complications & pitfalls
- Overdiagnosis and unnecessary anxiety/treatment in healthy positives
- Missed connective tissue disease if symptoms ignored
- Inappropriate repeat ANA testing
- Delayed diagnosis of evolving disease
Exam pearls
- ANA is positive in 5-15% of healthy people, more with age - a positive result alone does not diagnose disease
- Repeating the ANA is rarely useful; order specific antibodies instead
- Anti-dsDNA and anti-Sm are specific for SLE; centromere and Scl-70 for systemic sclerosis
- Nailfold capillaroscopy and Raynaud help identify early connective tissue disease
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.